Leerink Partners on Agios Pharma (AGIO): NVO's Ph3 trial results likely to pressure shares

April 20, 2026 10:14 AM

Leerink Partners analyst Andrew Berens reiterated an Outperform rating and $60.00 price target on Agios Pharma (NASDAQ: AGIO)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found